Table 3.
Groups | Cases | Before modeling (1/0.9 μl) | After modeling (1/0.9 μl) | After 4 weeks of injection (1/0.9 μl) |
---|---|---|---|---|
Saline | 8 | 5.15±0.14 | 9.92±0.75 | 9.90±0.77 |
pVAX1 | 8 | 5.14±0.13 | 9.95±0.74 | 9.94±0.73 |
pVAX1-ADM (low-dose) | 8 | 5.13±0.15 | 9.91±0.77 | 8.42±0.54* |
pVAX1-ADM (mid-dose) | 8 | 5.11±0.14 | 9.94±0.72 | 6.85±0.45*,# |
pVAX1-ADMg (high-dose) | 8 | 5.15±0.15 | 9.98±0.75 | 5.95±0.37*,#,@ |
Comparison with the saline group and pVAX group,
P<0.05; comparison with the pVAX1-ADM low-dose group,
P<0.05; comparison with the pVAX1-ADM mid-dose group,
P<0.05.